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ANTI-OVARIAN CANCER EFFECTS OF  
HISTONE DEACETYLASE INHIBITORS AND CALPAIN INHIBITOR 
KAROLINA EVA LAPINSKA 
ABSTRACT 
Ovarian cancer is the leading cause of death among gynecologic malignancies. 
The risk of developing ovarian cancer in a woman’s lifetime is 1 to 2 in 100. This high 
rate of development and death from the tumorigenesis is a result of its asymptomatic 
manifestation. Ovarian cancer is usually found in its advanced stage; therefore the 
survival rate is lower than for other types of cancers. The most common type of ovarian 
cancer, serous epithelial ovarian cancer, arises from the surface epithelium of the ovary 
and less frequent from the fallopian tubes or uterus. The treatment of surgery is limited 
by the fact that most ovarian cancers are detected after they have metastasized. 
Chemotherapy is often difficult because of the lack of sufficient target specific drugs. 
Typically, platinum in combination with other drugs is provided as the standard treatment. 
These combinations exhibit higher toxicity, are often not target specific, and frequently 
despite treatment, the tumor relapses. Current studies suggest epigenetics plays a 
significant role in carcinogenesis by the silencing of tumor suppressor genes (TSG). 
Histone modifications and the methylation of specific cytosine phosphate guanosine 
(CpG) residues in the upstream region of genes silence the TSG. Many clinical trials are 
in progress to develop combination therapies utilizing histone deacetylase inhibitors 
(HDACi), and DNA methyl transferase I (DNMTI) inhibitors, in combination with other 
cytotoxic agents. HDACi are known to be effective against different types of leukemia’s, 
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such as Cutaneous T-cell Lymphoma; however, they are not as effective against solid 
tumors when used as a single agent. Our laboratory was one of the first to demonstrate 
that HDACi, in addition to its known property to increase histone acetylation, 
additionally decrease CpG island methylation in the upstream region of TSG. This 
demethylation causes re-expression of TSG. Our laboratory hypothesizes that re-
expression of TSG sensitize cancer cells to other cytotoxic drugs. In an effort to develop 
improved therapy for ovarian cancer, we employed a combination therapy, which 
includes epigenetic drugs, HDACi, in combination with calpain protease inhibitor, 
calpeptin. Calpain is a ubiquitous protease usually activated in cardiovascular diseases 
and cancer cells. The present study discerns that combination of HDACi and calpeptin 
produce more than additive growth inhibition of diverse ovarian cancer cells. HDACi re-
expressed TSG. Additionally, the observed growth inhibition of ovarian cancer cells was 
caused by cell-cycle arrest, induction of apoptosis, followed by autophagy. The 
phosphorylation of growth promoting signaling protein, Mitogen Activated Protein 
Kinase 1 (ERK), was inhibited. In addition, the inhibitors also partially inhibited 
phosphorylation of anti-apoptotic protein V-ask Murine Thyomoma Viral Oncogene 
Homolog 1 (Akt). Collectively, the outcome of this study suggests that epigenetic drugs 
(HDACi) sensitize the diverse ovarian cancer cell lines by re-expression of TSG, 
followed by cell death, when treated in combination with calpain inhibitor, calpeptin. 
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INTRODUCTION 
Approximately 20,000 women in the United States succumb to ovarian cancer 
each year [1]. These carcinomas are the eighth most common and the fifth leading cause 
of cancer deaths in women [1]. It is the source of more deaths in females as compared to 
any other gynecologic cancer. These ovarian carcinomas vary in their classification of 
cell types: serous, endometrioid, mucinous, and Brenner tumors. This heterogeneity is 
further categorized into benign, intermediate, and malignant clinical manifestations. 
These differences arise from the precise mechanisms of either inherited or sporadic 
ovarian tumorigenesis; however, they are not well understood [2]. Nevertheless, 
alterations in many gene expressions, which are observed to be involved in various 
cancers, such as shared genetic markers BRCA, HER2, ER, PR, and ARHI in breast 
cancers, are also implicated in ovarian cancer [3] [4]. Currently, most available 
chemotherapies for ovarian cancer are not target specific [5]. The chemotherapeutic 
agents, such as platinum-taxol combinations, are being used in treatment of ovarian 
cancer. These treatments are relatively ineffective and nonspecific, targeting both healthy 
and malignant tissues [6] [7]. Thus, overcoming the resistance and recurrence that 
develops in 30-40% of women by novel treatments and new therapeutic targets is 
necessary to successfully treat patients [8]. Recent research suggests that in addition to 
genetic alterations, epigenetic changes are associated with numerous pathway genes in 
ovarian cancer [9]. Our laboratory proposes that combination therapies involving 
epigenetic drugs are beneficial in combating drug resistance, and in decreasing toxicity. 
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The combination therapy will also exhibit more than an additive anti-cancer effect [10] 
[11]. 
Altered epigenetic modulation of gene expression is a progression involved in 
various carcinomas. This modification manifests primarily through two mechanisms: 
histone modification and DNA methylation [12]. Increased regulation is involved around 
tightly bound basic proteins on DNA known as histones. The fundamental and structural 
arrangements of histones organize and condense the DNA molecules into chromosomes 
that are segregated during cell division. The amino acid residues on the histone tails are 
post-transcriptionally modified by acetylation, methylation, phosphorylation, and 
ubiquitination [13]. Histone acetylation and deacetylation is mediated by histone acetyl 
transferases (HATs) and histone deactylases (HDACs). Considerable data has shown 
abnormal histone modification as a cause of carcinogenesis [14]. With increasing 
therapeutic research, histone deacetylase inhibitors (HDACi) have shown promise [15]. 
HDACi result in increased acetylation activity of many intrinsic proapoptotic genes and 
are under clinical trials as anticancer agents. Recently, HDACi, such as suberoylanilide 
hydroxamic acid (SAHA, commercially known as Vorinostat), have been approved by 
the FDA in treatment of Cutaneous T-cell Lymphoma; however, HDACi are not useful in 
treating solid tumors [16]. Newly developed HDACi are under clinical trials in 
combination with other available drugs therapies against solid tumors, which include 
breast and ovarian cancers [17]. 
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 Another equally important epigenetic alteration observed during carcinogenesis is 
the silencing of tumor suppressor genes (TSG) by methylation of cytosine phosphate 
guanosine (CpG) islands around the promoter regions, as shown in Figure 1.  
 
Figure 1. Maintenance of Methylation by DNMTI. After replication, methylation (shown in red) of the 
specific CpG residues (not shown) on the mother strand is copied onto the daughter strand by DNA 
methyltransferase I (DNMTI), with preservation of the methylation pattern on the mother strand [18]. 
 
DNA methyltransferase I (DNMTI) is the enzyme that maintains methylation in 
the newly replicated strand of DNA during cell division, as shown in Figure 1. Usually, 
the expression of DNMTI varies during a cell cycle, being highest during the S phase 
[19]. In normal healthy cells, overall genome-wide methylation is higher, though specific 
regions near the promoters of TSG are hypomethylated. The reverse happens during 
carcinogenesis [20]. DNMTI is highly expressed in all types of cancer, even during cell 
cycle arrest; however, the genome wide methylation of cancer cells are reduced 
compared to normal cells [19] [20] [21]. One possible reason for hypomethylation in 
cancer cells could be the higher expression of growth promoting genes. The 
hypermethylated CpG residues by DNMTI around the promoter region of TSG in cancer 
cells, subsequently recruit histone deacetylase 1 (HDAC1) and methyl domain binding 
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protein 2 (MDBP2) [18]. These proteins hinder the binding of RNA polymerase II (RNA 
Pol II) to the promoter region, inhibiting transcription, as shown in Figure 2. Drug-
induced demethylation of these CpG residues in the upstream regions of TSG, releases 
HDAC1 and MDBP2 from the CpG site and transcription resumes [21]. 
 
 
Figure 2. De Novo Methylation by DNMTI and Recruitment of HDAC and MDBP. In de novo 
methylation, RNA polymerase II (RNA Pol II) and transcription factors bind to unmethylated upstream 
promoter region of a gene (shown in green), activating transcription. DNA methyl transferases (DNMTs) 
methylate specific CpG sites (not shown) within the promoter region. When a gene is methylated at CpG 
sites near the promoter region (shown in red), it allows binding of histone deacetylases (HDACs) and other 
methyl domain-binding proteins (MDBP) and prevents RNA Pol II from binding, thus inhibiting 
transcription. In addition, methylation in the intragenic region is seen, though the function is still not well 
understood [18]. 
 
Interestingly, genetic susceptibility to cancers has not been fully understood [22]. 
Genetic predisposition does not yet explain why people with the same types of genetic 
alterations or mutations develop cancer at different stages of their lives or why some 
develop and others do not [23]. Recent studies suggest that the environment plays an 
important role to induce carcinogenesis in these predisposed individuals [18] [21] [24]. 
One of the principal ways environmental factors, such as differential signaling 
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mechanisms and the differential effect of stromal cells on a tissue, induce carcinogenesis 
is most significantly revealed by the mechanisms of epigenetic alterations. This idea is 
supported by observations that conventional therapy is unable to kill cancer 
stem/progenitor cells and drug resistant cancer cells [25]. Our laboratory hypothesizes 
that epigenetic events initiate carcinogenesis and are also involved in cancer progression 
and metastasis, as shown in Figure 3 and 4 [4] [11] [21]. Recent studies have shown that 
treatment of platinum drug resistant ovarian cancer cells with epigenetic drugs made 
them susceptible to the platinum drugs once more [26]. Inhibiting the abnormal 
epigenetic progression may in fact kill drug resistant cancer cells, kill cancer 
stem/progenitor cells, inhibit epithelial-mesenchymal transition (EMT) of epithelial 
tumor cells, and perhaps mesenchymal-epithelial transition (MET) of circulating cancer 
cells [11]. 
 
 
Figure 3. Cancer Progenitor Cells and Progression of Cancer. Various epigenetic changes possibly 
initiate formation of cancer progenitor cells from predisposed cancer cells. The augmentation of cancer 
from the cancer progenitor cells is a consequence of the various environmental conditions and by certain 
intracellular alterations [20]. 
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Figure 4. Changes That Occur as a Tumor Cell Undergoes EMT and Subsequently Metastasizes at a 
Secondary Location. As epithelial tumor cells (shown in blue) undergo epithelial-mesenchymal transition 
(EMT), they begin to lose their epithelial phenotype (shown after step 2). The decrease of cell-to-cell 
attachment receptors and integrins (shown in purple) continues to step 3 and persists after. Additionally, 
stromal cells near the cancer cell undergoing EMT are affected and start experiencing changes (shown as a 
transition from green to red cells). Once the cancer cells have completely undergone EMT, they travel to a 
new location, and multiple steps (not shown) involving mesenchymal-epithelial transition (MET) must 
occur for the metastatic cancer cell to infiltrate at a distant site to form a secondary tumor. Now, the stromal 
cells at the new tumor location will likewise undergo transformation [11]. (ECM: Extracellular Matrix; 
MMP: Matrix Metalloproteinase) 
 
 Our laboratory has been one of the first to discern that HDACi, in addition to their 
known ability to increase acetylation, produce demethylation of CpG residues on DNA 
[27].  The demethylation is a result of degradation of DNMTI, which leads to re-
expression of TSG: p21and p16, and RARβ2 [27]. Our laboratory presented outcomes in 
which treatment with two structurally different Class I and Class II HDACi, Sodium 
Butyrate (SB) and SAHA, re-express TSG, ARHI, in breast cancer cells [3]. Sarkar et al. 
proposed, that if HDACi re-express TSG, then consequently they should sensitize the 
cancer cells to other cytotoxic drugs [21]. Thus, this is one of the central hypotheses of 
our laboratory for developing a combination therapy. In support of this hypothesis, our 
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laboratory has shown that HDACi sensitize both breast and ovarian cancer cells to 
different cytotoxic drugs, including oligonucleotides designed against telomeres and 
inhibitors of calpain protease [3] [28]. Many studies are underway which involve the use 
of both HDACi and DNMTI inhibitors in combination with other drugs against solid 
tumors [4] [10].  
In this study we investigated the effects of HDACi in combination with calpain 
protease inhibitor, calpeptin, on ovarian cancer cells. We employed two discrete ovarian 
cancer cells, namely CAOV-3 and SKOV-3. CAOV-3 is tumor suppressor protein p53 
(TP53) mutated, while SKOV-3 is TP53 null. The distinction between the two is clearly 
noted in the differences of their response to our combination therapy. Recognizing the 
differences, CAOV-3 is understood to be less aggressive and less metastatic than SKOV-
3. The combination of the two inhibitors, HDACi and calpeptin, produced enhanced 
growth inhibition in these ovarian cancer cells. Additionally, we identified the 
mechanisms of actions of the inhibitors. The inhibitors (i) inhibited cell cycle, (ii) 
decreased metastatic activity, (iii) induced apoptosis, and (iv) promoted autophagy. (v) 
TSG: ARHI, p21, and RARβ2 were re-expressed and (vi) we observed differential 
inhibition of two important signaling pathways, v-ask murine thyomoma viral oncogenes 
homolog 1 (Akt) and extracellular signal-regulated kinase (ERK). Thus, the 
comprehension and knowledge of the mechanisms involved in the growth inhibition and 
the death of ovarian cancer cells is essential to fully appreciate the usefulness of this 
combination therapy. 
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MATERIALS AND METHODS 
 
1. Cell Culture 
 
CAOV-3 and SKOV-3 ovarian cancer cells were grown in Roswell Park 
Memorial Institute (RPMI-1640) media containing 100 IU/mL penicillin, 100 µg/mL 
streptomycin, and 50 mL 10% heat-inactivated fetal bovine serum (FBS). Around 70-
80% confluence, cells were exposed to dimethyl sulfoxide (DMSO) (control) or distinct 
concentrations of inhibitors. Cells were incubated for different times before being 
harvested. 
 
2. Reagents 
 
CAOV-3 and SKOV-3 ovarian cancer cells were obtained from American Type 
Culture Collection (Manassas, VA). SB and SAHA were purchased from Sigma (St. 
Louis, MO) and calpeptin was purchased from Nova Chemicals (Moon Township, PA). 
RPMI-1640 and Dulbecco’s Modified Eagle Medium (DMEM) were obtained from 
Invitrogen (Carlsbad, CA). The annexin/PI apoptosis analysis kit was acquired from BD 
Biosciences (San Diego, CA). The cDNA preparation kit was obtained from Qiagen 
(Valencia, CA). The SYBR green RT-PCR mix was from Applied Biosciences (Foster 
City, CA). Diff-Quik Stain was obtained from IMEB Inc. (San Marcos, CA). All 
antibodies, including anti-phospho ERK, anti-ERK, anti-phospho-Akt, anti-Akt, and anti-
L3Cb were obtained from Santa Cruz Biotech (Paso Robles, CA). The western blot 
developer was acquired from Thermo Scientific (Rockford, IL). 
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3. Cell Survival Assay 
 
Equal number of ovarian cancer cells were grown in six-well plates and treated 
with desired concentrations of inhibitors, as described in the legend of Figures 5 (A and 
B). After 96 hours, viable cells were counted using a trypan blue exclusion assay. The 
media was aspirated and cells were washed with PBS. The cells were trypsinized and 20 
µL cell suspensions were mixed with 20 µL trypan blue. The unstained (viable) cells 
were counted. The viable cell number in control (untreated) cells were plotted as 100%.  
Viable cell counts in inhibitor treated samples were normalized to the percentage 
compared to the control. 
4. In-Vitro Cell Migration Assay 
 
The effects of inhibitors on migration of the cells were tested by chemotaxis assay. 
This assay was performed in 24-well plates and contained transwell chambers with 
membranes, which included 8 µm pores. The cells were treated with specific 
concentrations, as described in the legend of Figure 6 (A and B), harvested two days later 
by trypsinization, and washed in serum-free RPMI growth medium. The upper chamber 
received 200,000 cells suspended in 500 µL serum-free RPMI growth medium and the 
lower chamber received 0.5 mL of conditioned media from the actively growing ovarian 
cancer cells. After 12 hours, the cells from the chambers were aspirated and wiped with 
cotton swabs. The membranes were stained with Diff-Quik Stain, obtained from IMEB 
Inc. (San Marcos, CA), and the migrated cells were viewed under a light microscope and 
counted. 
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5. Real-time Quantitative PCR (qPCR) 
 
Ovarian cancer cells were grown in 10cm plates, treated with inhibitors as 
described in the legend of Figure 7 (A and B) and harvested. The total RNA was isolated 
using Trizol reagent (Invitrogen), according to the manufacturer’s protocol. The RNA 
was converted to cDNA after digesting any genomic DNA contamination. Real-time 
quantitative PCR was performed using prepared cDNA. Results were normalized to the 
expression level of β-actin transcripts within each sample with the same primers.  
Table 1. List of Primers Used for RT-PCR. 
Primer 
Name Forward (5’!  3’) Reverse (5’!  3’) 
ARHI TGGGTAACGCCAGCTTTGGCT TAACGTGGCGCGTGCAGAGCG 
RARβ2 CAAACCGAATGGCAGCATCGG GCGGAAAAAGCCCTTACATCC 
p21 CTGGAGACTCTCAGGGTCGAA GGATTAGGGCTTCCTCTTGGA 
β-actin CTGGCACCCAGCACAATG GGACAGCGAGGCCAGGAA 
 
 
6. Cell Cycle and Apoptosis Assays 
 
Ovarian cancer cells were treated with inhibitor concentrations, as described in 
the legend of Figure 8 (A, B, C, and D). Untreated control cells and treated cells were 
washed with phosphate buffered saline (PBS). For cell cycle analysis, cells were fixed 
with a medium containing 35% ethanol for 5 minutes at room temperature. The cells 
were stained for 30 minutes in the dark with 25 µg/mL propidium iodide (PI), containing 
50 µg/mL RNAse in PBS, and then underwent FACS analysis. The apoptosis assay was 
performed with the annexin/PI assay. After treatment, untreated and treated cells were 
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harvested and suspended in 100 µL 1x binding buffer. Subsequently, 5 µL annexin 
reagent conjugated to fluorescein isothiocynate (FITC) and 5 µL PI were added to each 
sample as described in the kit protocol (BD Biosciences). The samples were kept in the 
dark for 30 minutes at room temperature. 900 µL 1x binding buffer was added to each 
sample follow by the measurement of the dual fluorescence of FITC and PI, in the FACS 
machine. 
7. Immuno Staining Procedure and Autophagy Assay 
Ovarian cancer cells were grown in eight-well plates and treated with inhibitors, 
as described in the legend of Figure 8 (G and H). Media was then aspirated from each 
well. The cells were fixed for 15 minutes with 200 µL 4% paraformaldehyde at room 
temperature and washed with PBS three times. Next, cells were treated for 30 minutes 
with 200 µL solution, including 0.1% Triton X100 and 0.1% sodium citrate, at room 
temperature. The solution was aspirated, the wells washed 3 times with PBS, and then 
blocked for 1 hour with 300 µL bovine serum albumin (BSA) at room temperature. The 
solution was aspirated and the wells washed three times with PBS. The primary anti-
LC3b was added in 3% BSA to the wells and incubated at 4°C overnight. The following 
day, the solution was aspirated and the wells were washed three times with PBS. An 
appropriate dilution of secondary antibody in 3% BSA (conjugated to FITC) was added 
and incubated for one hour at room temperature. The solution was aspirated and the wells 
washed three times with PBS. Then, 100 µL DAPI (Invitrogen) was added to each well 
and incubated for 5-10 minutes. The solution was aspirated and the wells washed three 
times with PBS. A drop of mounting solution (Prolong Gold, Invitrogen) was added to 
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each slide and a cover slip placed to hold in position. Each slide was sealed with nail oil, 
dried, and viewed and photographed under fluorescent microscope.  
8. Protein Immunoblot Analysis 
Ovarian cancer cells were grown in 10cm plates and treated with inhibitors, as 
described in the legend of Figure 9 (A and B). The cells were harvested with 
trypsin/EDTA, washed with PBS, and collected by centrifugation at 1,000 rpm. 
Subsequently, cells were lysed with ice cold 1% NP-40 lysis buffer, including vanadate 
and protease inhibitor cocktail tablet (1 tablet/10ml buffer) (Roche, Germany). For each 
sample, protein concentrations were calculated with BSA as the control, using a protein 
assay reagent (Bio-RAD). Equal amount of protein from each sample was resolved by 
SDS-PAGE and transferred to a nitrocellulose membrane. The membrane was blocked 
with 3% non-fat milk powder or 5% BSA for phospho blots in Tris-Buffered 
Saline/Tween (TBST) and then incubated with the primary antibody at 4°C overnight. 
The membrane was washed with TBST three times for 10 minutes each. The secondary 
antibody was conjugated to horseradish peroxide (HRP), added, and then membrane was 
incubated for one hour at room temperature. The membrane was washed with TBST three 
times for 10 minutes, and was developed using a chemiluminescent reagent, and 
photographed using Image Quant (GE LAS4000). 
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RESULTS 
 
1. Combination Treatment of HDACi and Calpeptin: Growth Inhibition and 
Morphological Changes in Ovarian Cancer Cells 
 
To test the efficacy of the combination therapy, two characteristically different 
ovarian cancer cells lines, SKOV-3 and CAOV-3, were used in this study. These cells 
were treated with sub-optimal levels of chemically distinct HDACi (SB and SAHA) and 
calpain protease inhibitor, calpeptin. The combination treatment of HDACi and calpeptin 
resulted in a notable 80-90% inhibition of growth of the ovarian cancer cells after four 
days (Figure 5A and B). This decrease in growth reveals a significant effect of the 
combination therapy (SB and Calp: p value = 0.0002, and SAHA and Calp: p value = 
0.0001, for CAOV-3 cells; and p value = 0.0001 for both combinations in SKOV-3 cells), 
since the effective dose of each HDACi and calpeptin was lower than the effective doses 
of HDACi and calpeptin when used as a single agent (not shown).  
Distinct morphological changes were observed both in CAOV-3 and SKOV-3 
ovarian cancer cells after treatment with the inhibitors. After four days, the cells 
decreased in number and assumed a more rounded shape with the addition of HDACi 
with calpeptin, which suggests cell death (Figure 5C and D). The distortion of cell 
structure in both ovarian cancer cell lines was more obvious when treated with calpeptin.  
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Figure 5. Growth Inhibition and Morphological Changes of CAOV-3 and SKOV-3 Ovarian Cancer 
Cells by HDACi and Calpeptin. A. CAOV-3 ovarian cancer cells were treated with 0.5 mM sodium 
butyrate (SB), 2 µM SAHA, 5 µg/mL calpeptin (Calp) or combination of SB and Calp (p value = 0.0002), 
and SAHA and Calp (p value = 0.0001), at the same concentrations. B. SKOV-3 ovarian cancer cells were 
treated with 1 mM SB, 10 µM SAHA, 10 µg/mL Calp or combination of SB and Calp (p value = 0.0001), 
and SAHA and Calp (p value = 0.0001), at the same concentrations. Viable cells were washed, trypsinized, 
and counted after four days. All treated cells are expressed as a percent relative to the arbitrarily set 100% 
of the dark shaded column of control cells. C. CAOV-3 ovarian cancer cells were treated with 1 mM SB, 
10 µM SAHA, 20 µg/mL Calp, or a combination of SB and Calp, and SAHA and Calp, at the same 
concentrations. D. SKOV-3 ovarian cancer cells were treated with 1 mM SB, 10 µM SAHA, 20 µg/mL 
Calp, or a combination of SB and Calp, and SAHA and Calp, at the same concentrations. Morphology 
changes and number of cells are different in the cells with inhibitors when compared to the control cells. 
Photographs were taken after four days treatment. 
 
2. Inhibition of Motility by HDACi and Calpeptin. 
Growth inhibition does not necessarily imply that the inhibitors would be 
effective against a cancer cell’s metastatic property. Therefore, we determined the effects 
of HDACi and calpeptin on the invasiveness property of ovarian cancer cells. As a 
marker of invasive potential, the degree of motility of ovarian cancer cells was assessed 
by an in-vitro cell migration (transwell) assay [11]. Conditioned media from the untreated 
control cells was used as a chemo-attractant. The inhibitor-treated cells and untreated 
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control cells were placed in the upper chambers and the conditioned media was added to 
the lower chamber. The movement of the cells across the membrane separating the two 
chambers was measured by staining the cells that crossed the membrane. The number of 
control, untreated cells, which moved across the membrane, was assigned as 100% of 
cells being motile. The percent of treated cells, which moved across the membrane, were 
plotted (Figure 6). Approximately 70-90% reduction in motility of both CAOV-3 and 
SKOV-3 ovarian cancer cells was observed in HDACi and calpeptin treated cells (Figure 
6A CAOV-3 and 6B SKOV-3, respectively). The combination, at the concentrations used, 
did not produce any additional inhibition. 
 
Figure 6. Transwell Inhibition of CAOV-3 and SKOV-3 Ovarian Cancer Cell Motility. A. CAOV-3 
ovarian cancer cells were treated with 0.5 mM sodium butyrate (SB), 2 µM SAHA, 5 µg/mL calpeptin 
(Calp) or combination of SB and Calp, and SAHA and Calp, at the same concentrations. B. SKOV-3 
ovarian cancer cells were treated with 1 mM SB, 10 µM SAHA, 10 µg/mL Calp or combination of SB and 
Calp, and SAHA and Calp, at the same concentrations. After 48 hours, ovarian cancer cells were harvested, 
suspended in serum-free media and added to the upper chamber. The lower chamber contained conditioned 
media from control cells. After 12 hours, cells were removed from the upper chamber and the membrane 
was stained and viewed under the microscope. Cell counts were taken. Untreated control cell counts were 
normalized to 100% motility. HDACi, Calp, and combination treatment results are shown in percentage 
motility compared to the control. 
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3. Re-expression of Tumor Suppressor Genes by HDACi 
 
Our laboratory has previously demonstrated that treatment with HDACi caused 
demethylation of methylated CpG islands in the upstream regions of tumor suppressor 
genes (TSG). Demethylation re-expressed these silenced TSG [3,28]. Three TSG: ARHI, 
p21, and RARβ2 are epigenetically silenced during ovarian carcinogenesis. ARHI is a 
maternally imprinted, pro-apoptotic TSG. Normally, in healthy tissue, ARHI is expressed 
only from the paternal allele. In 40% of breast and ovarian cancer, the paternal allele is 
silenced causing a loss of heterozygosity [4,21]. p21 is a cell cycle inhibitor and RARβ2 
is a marker of differentiation. To determine the status of these three TSG after HDACi 
and calpeptin treatment, we performed qPCR assays with treated and untreated ovarian 
cancer cells. HDACi, 10 µM SAHA, resulted in a 6-fold re-expression of ARHI in 
CAOV-3 ovarian cancer cells and a 2.2-fold re-expression of ARHI in SKOV-3 ovarian 
cancer cells, with respect to each untreated control cells (Figure 7A and B, ARHI). p21  
re-expression with 10 µM SAHA produced a 5-fold increase in CAOV-3 ovarian cancer 
cells and 8-fold increase in SKOV-3 ovarian cancer cells (Figure 7A and B, p21). RARβ2 
re-expression was enhanced 85-fold in CAOV-3 ovarian cancer cells and 6-fold in 
SKOV-3 ovarian cancer cells after treating with 10µM SAHA. (Figure 7A and B, 
RARβ2). 
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Figure 7. Re-expression of Tumor Suppressor Genes: ARHI, p21, RARβ2. A. CAOV-3 ovarian cancer 
cells were treated with 10 µM SAHA for 48 hours. B. SKOV-3 ovarian cancer cells were treated with 10 
µM SAHA for 48 hours. Total RNA was isolated, then cDNA was prepared. qPCR for ARHI, p21, and 
RARβ2 transcripts were performed. The results were normalized for each sample to the level of β-actin 
transcripts for each gene in each sample. Data was expressed as a fold re-expression compared to the 
control cells.  
4. Inhibition of Cell Cycle, Induction of Apoptosis, and Autophagy 
The results from the inhibition of growth and re-expression of TSG, including cell 
cycle inhibitor p21 and pro-apoptotic gene ARHI, suggested our laboratory to test both 
cell cycle inhibition and apoptosis by HDACi and calpeptin. CAOV-3 and SKOV-3 
ovarian cancer cell lines displayed a relatively similar type of cell cycle phase inhibition 
with the addition of SB, SAHA, and calpeptin (Figure 8A and B). All treated CAOV-3 
ovarian cancer cells were arrested in the S-phase of the cell cycle. The CAOV-3 cancer 
cells treated with combination of both SB and SAHA with calpeptin exhibited a 
significant 16-18% S-phase arrest, with the amount of cells in the G1 phase being 
relatively lower (all compared to its respective untreated control cells) (Figure 8A). 
Similar to the CAOV-3 cancer cells, the SKOV-3 ovarian cancer cells exhibited S-phase 
arrest; however, certain drug-treatments portrayed considerably increased inhibition than 
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the CAOV-3 cancer cells (Figure 8B). SKOV-3 cells treated with SB, calpeptin, and 
combination of SB and calpeptin presented a substantial cell cycle arrest in the S-phase. 
SAHA and calpeptin combination treated SKOV-3 cancer cells were significantly 
arrested in the G2/M phase of the cell cycle (13-14%), as compared to their respective 
untreated control cells.  
In order to determine whether the cell death observed from the morphological 
alterations (Figure 5C and D) was caused by induction of apoptosis and autophagy, we 
investigated both possibilities to discern the methodologies. Firstly, to measure apoptosis, 
the annexin/propidium iodide (PI) assay was utilized [27]. Annexin is bound to the inner 
surface of the plasma membrane. When the cell undergoes the early phase of apoptosis, 
the membrane flips, resulting in exposure of annexin to the external environment. PI 
binds the released inactive and nuclear DNA during apoptosis. The combination of 
annexin and PI attachment provides a comprehensive measurement of all the phases of 
apoptosis. As shown in Figure 8C and D, CAOV-3 and SKOV-3 ovarian cancer cells 
exposed to HDACi and calpeptin exhibited an increase in apoptosis at the given 
concentrations. The lower right (LR) quadrant depicts cells in the early stage of apoptosis. 
This is the point when the cell membrane reverses and only allows annexin to bind. The 
increase in apoptosis presented in the results however, was more pronounced in the later 
phases of apoptosis, as observed from the upper right (UR) and upper left (UL) quadrants 
values (Figure 8C and D).  UR is the intermediate stage of apoptosis when the membrane 
is flipped and the DNA in nucleus is becoming increasingly accessible to PI. UL is the 
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late stage of apoptosis, when the cell membrane has completely fallen apart and the entire 
DNA is exposed. Essentially at this stage, all the cells are dead. 
SKOV-3 ovarian cancer cells portrayed a much higher apoptosis percentage when 
treated with HDACi, calpeptin, and combination treatments; however, analogously 
increased results were observed when both ovarian cancer cells lines were treated with 
the combination of SAHA and calpeptin. Figure 8E and F demonstrated the total 
apoptosis of CAOV-3 and SKOV-3 ovarian cancer cells after the treatments. 
The induction of autophagy similarly plays a role in cancer cell death. The 
morphological changes observed in Figure 5C and D indicate that treated cancer cells 
possibly underwent autophagy, particularly calpeptin-treated ovarian cancer cells. This 
likelihood is supported by the observation that ARHI is re-expressed by HDACi (Figure 
7A and B, left panel). ARHI is also known to induce autophagy in cancer cells [21] [29]. 
With these reasons we determined the status of autophagy in HDACi and calpeptin 
treated CAOV-3 and SKOV-3 ovarian cancer cells. During autophagy, lysosomes fuse 
with vesicles containing the isolated constituents of the cell to produce phagolysosomes, 
in which the cargo materials are degraded. Cytoplasmic protein, LC3b, translocates to the 
phagolysosomal membrane during this process. Detection of LC3b on the phagolysosome 
membrane by the immuno staining procedure is a measure of autophagy. The 
translocation of LC3b was portrayed in different patterns after treatment with certain 
drugs in CAOV-3 and SKOV-3 ovarian cancer cells (Figure 8G and H). In CAOV-3 
ovarian cancer cells, the LC3b protein was primarily associated with the phagolysosomes 
in increased amount after calpeptin treatment and SAHA and calpeptin combination 
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treatment (Figure 8G). In contrast, in SKOV-3 ovarian cancer cells, both HDACi and 
calpeptin treated cells portrayed the LC3b protein around phagolysosomes (Figure 8H). 
Furthermore, the shape of the SKOV-3 ovarian cancer cells were more contorted in an 
elongated shape as compared to the CAOV-3 ovarian cancer cells. However, in both cell 
lines, LC3b association was more pronounced in SAHA and calpeptin combination 
treatments. Untreated controls cells showed a diffused staining of lower intensity in the 
cytoplasm. 
Taken together, the results from cell cycle arrest, apoptosis induction, and 
induction of autophagy, provided mechanisms of how the number of live ovarian cancer 
cells decreased with HDACi and calpeptin combination therapy. The data observed on 
CAOV-3 and SKOV-3 ovarian cancer cells, at given concentrations, suggest overlapping 
of all these processes in the inhibition of cell growth and in cell death.  
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Figure 8 A-F. Cell Cycle Inhibition and Apoptosis. A. CAOV-3 ovarian cancer cells were treated for 48 
hours with 1 mM sodium butyrate (SB), 10 uM SAHA, and 10 ug/mL calpeptin (Calp) or combination of 
SB and Calp, and SAHA and Calp, at the same concentrations. B. SKOV-3 ovarian cancer cells were 
treated for 48 hours with 1 mM SB, 10 uM SAHA, and 10 ug/mL Calp or combination of SB and Calp, and 
SAHA and Calp, at the same concentrations. The cells were stained with PI and FACS analysis was 
performed to determine the stages of cell cycle inhibition in each sample. C. CAOV-3 ovarian cancer cells 
were treated with 1 mM SB, 10 uM SAHA, and 10 ug/mL Calp or combination of SB and Calp, and SAHA 
and Calp, at the same concentrations. D. SKOV-3 ovarian cancer cells were treated with 1 mM SB, 10 uM 
SAHA, and 10 ug/mL Calp or combination of SB and Calp, and SAHA and Calp, at the same 
concentrations. After a 48-hour treatment, the ovarian cancer cells were stained with annexin conjugated to 
FITC and PI. Apoptosis quantities were measured with flow cytometry and plotted. E. Graph representation 
of CAOV-3 cancer cell apoptotic percentages from data of C. F. Graph representation of SKOV-3 cancer 
cell apoptotic percentages from data of D 
 
 
 22 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8 G-H. Autophagy. G. CAOV-3 ovarian cancer cells were treated for 96 hours with 0.5 mM SB, 2 
µM SAHA, 5 µg/mL Calp or combination of SB and Calp, and SAHA and Calp at the same concentrations. 
H. SKOV-3 ovarian cancer cells were treated for 96 hours with 1 mM SB, 10 µM SAHA, 10 µg/mL Calp 
or combination of SB and Calp, and SAHA and Calp at the same concentrations. Next, cells were treated 
with antibodies followed by DAPI addition and incubated. Cells were viewed and photographed with a 
fluorescent microscope. 
 
5. Effects of HDACi and Calpeptin on the phosphorylation of ERK and Akt 
Recent work from our laboratory has revealed that HDACi inhibit ERK 
phosphorylation in prostate and breast cancer cell lines [27]. ERK activation is known to 
activate many pro-growth pathways by inducing the expression of genes involved. 
Research from other laboratories has shown that calpeptin inhibits Akt phosphorylation 
[30]. Akt activity is important for cell survival and often enhanced in cancer cells. 
Interestingly, in addition to their role in major signaling pathways, both ERK and Akt 
have been shown to regulate methylation of genes silenced in cancer cells [10] [21]. To 
determine whether HDACi and calpeptin inhibit phosphorylation of ERK and Akt in 
ovarian cancer cells, a western analysis of HDACi and calpeptin treated and untreated 
ovarian cancer cells was performed. Figure 9A (upper left) showed reduced 
phosphorylation of Akt in CAOV-3 ovarian cancer cells when the cells were treated in 
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combination with either HDACi SB or SAHA with calpeptin. In contrast, SKOV-3 
ovarian cancer cells did not show much inhibition of phosphorylation of Akt (Figure 9A, 
upper right).  
Analysis of ERK phosphorylation provided different results in CAOV-3 and 
SKOV-3 ovarian cancer cells. Results from these experiments demonstrated that CAOV-
3 cancer cells had decreased phosphorylation of ERK when exposed to SAHA, as 
compared to the untreated control cells (Figure 9B, lower left). Calpeptin did not produce 
much decrease in ERK phosphorylation in CAOV-3 cancer cells by itself; however, the 
combination treatments demonstrated significant inhibition. It is important to note that 
SB, at the concentration used (1mM) was not as effective as SAHA (10 µM), which is a 
much better inhibitor. SKOV-3 ovarian cancer cells showed a similar inhibition pattern of 
ERK phosphorylation as in CAOV-3 cancer cells (Figure 9B, lower right). The lower 
panel of each figure demonstrate similar loading of Akt and ERK, respectively.  
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Figure 9. Effects of HDACi and Calpeptin on Akt and ERK phosphorylation. A. CAOV-3 ovarian cancer 
cells (upper left panel) and SKOV-3 ovarian cancer cells (upper right panel) were treated with 1 mM 
sodium butyrate (SB), 1 uM SAHA, 20 ug/mL calpeptin (Calp), or combination of SB and Calp, and 
SAHA and Calp, at the same concentrations. Western analysis was performed for Akt phosphorylation 
(pAkt) in CAOV-3 and SKOV-3 ovarian cancer cells. B. CAOV-3 ovarian cancer cells (lower left panel) 
and SKOV-3 ovarian cancer cells (lower right panel) were treated with 1 mM SB, 10 uM SAHA, 20 ug/mL 
calpeptin (Calp), or combination of SB and Calp, and SAHA and Calp, at the same concentrations. Western 
analysis was performed for ERK phosphorylation (pERK) in CAOV-3 and SKOV-3 ovarian cancer cells. 
Blots were stripped and a western blot followed for Akt and ERK, respectively. 
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DISCUSSION 
 
Epigenetics is a relatively new field in the realm of scientific discoveries. 
However, since its recognition in the 1980’s, epigenetic drugs have already been 
approved for certain types of leukemia and T-cell lymphoma’s [16]. Recent clinical trials 
though, have shown that epigenetic drugs (i.e. DNMTI inhibitors and HDACi) do not 
work well in solid tumors when used as a single agent [4] [10]. Even the combination of 
two types of epigenetic drugs is not as effective against solid tumors. Our laboratory 
hypothesized that the combination of epigenetic drugs with other cytotoxic drugs, such as 
chemotherapeutics, should be more effective against solid tumors [4] [11] [18] [21]. Our 
premise was based on the observation that epigenetic drugs, such as HDACi alone or in 
combination with DNMTI inhibitors, re-express TSG, which should sensitize cancer cells 
towards other chemotherapeutic agents [21] [31]. In fact, our laboratory and other 
investigators have determined that HDACi in combination with additional inhibitors are 
very successful against breast and ovarian cancer cells. One study described HDACi in 
combination with inhibitory antibody to death receptor 4 (DR4) reduced breast cancer in 
a xenographed tumor model [31]. Additionally, we previously demonstrated that HDACi 
combined with telomere analogues GT oligonucleotides were effective against ovarian 
cancer cells of diverse characteristics [28] [33]. Our laboratory has also established that 
HDACi in combination with calpeptin induced growth inhibition of both estrogen 
responsive and triple negative breast cancer cell lines [3].  
In this study, we presented results that validated that the combination of HDACi 
with calpain protease inhibitor, calpeptin, produced enhanced growth inhibition of two 
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ovarian cancer cell lines of different characteristics, (i) CAOV-3 (TP53 mutated) and (ii) 
SKOV-3 (TP53 null and highly metastatic). We employed two structurally different Class 
I and Class II HDACi, sodium butyrate (SB) and SAHA, respectively, to determine that 
the effects we observed were certainly due to the inhibition of HDAC activity. We chose 
to utilize calpeptin as the other drug in our combination treatment since calpain has been 
shown to regulate many signaling pathways, including Akt, which are involved in cellular 
growth and apoptosis [34]. Additionally, our laboratory and others have previously 
shown that the inhibition of calpain has anti-thrombotic properties [35] [36]. Calpain 
plays a significant role in platelet activation and is highly activated during thrombosis 
[35]. Treatment of ovarian cancer cells with high concentrations of HDACi or calpeptin 
was capable of inhibiting growth (not shown). We however performed a titration of 
concentrations for all inhibitors and chose sub-optimal concentrations of each, which do 
not inhibit the growth significantly when used as a single agent (Figure 5). The reasoning 
behind these sub-optimal concentrations was to demonstrate that the combination of 
HDACi and calpeptin produce a greater inhibition of ovarian cancer cell growth than the 
inhibitors alone, when used at the same sub-optimal doses (Figure 5A and B). 
Interestingly, the combination doses of both HDACi and calpeptin were lower for 
CAOV-3 than for SKOV-3 ovarian cancer cells. This is consistent with the fact that 
SKOV-3 cancer cells are a more aggressive and resistant ovarian cancer cell line, which 
is difficult to treat. These results additionally suggested that these types of combinations 
can be used against diverse types of ovarian cancer cell lines and that the effective doses 
will vary as well. Interestingly, the addition of calpeptin further drastically altered the 
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morphology of both types of ovarian cancer cell lines (Figure 5C and D). These results 
suggest the inclusion of calpeptin-induced cell death.  
In addition to uncontrollable cell growth, one of the characteristics of malignant 
tumors is metastasis. The aggressiveness of a tumor is dependent upon how motile the 
individual cancer cells are. Theoretically, the most effective drugs, in addition to 
inhibiting growth and promoting cell death, should inhibit metastasis as well. Many 
available chemotherapeutic agents are not effective against these two characteristics. 
Some drugs that inhibit metastasis are not effective in inhibiting cancer cell growth, and 
the opposite is true as well. Figure 6A and B demonstrated that both HDACi and 
calpeptin inhibited the motility of both CAOV-3 and SKOV-3 ovarian cancer cell lines. 
Though the individual inhibitors and combinations showed similar effects, we believe 
that HDACi and calpeptin concentrations used for this experiment were substantial 
enough to inhibit cell motility even when used as a single agent. To determine whether 
the combination would produce a more significant outcome, a separate experiment would 
need to be generated to titrate HDACi and calpeptin and discover the sub-optimal doses. 
Nonetheless, collectively, the results (Figures 5 and 6) showed that the combination of 
HDACi and calpeptin inhibited growth and reduced tumor cell motility. 
Successively, we further investigated the mechanisms of growth inhibition of 
these ovarian cancer cells after drug treatments. As described in the introduction, our 
laboratory has demonstrated that HDACi degrade DNMTI and thus demethylate CpG 
residues in the upstream region of TSG [21] [28]. Figure 7A and B showed that three 
TSG: ARHI, p21, and RARβ2 were re-expressed in both CAOV-3 and SKOV-3 ovarian 
 28 
cancer cell lines after treatment with HDACi SAHA. These three TSG have distinctly 
different functions. ARHI is an imprinted pro-apoptotic gene, which is similar to RAS, a 
proto-oncogene, but opposite in function [32]. The maternal allele of ARHI is silenced by 
methylation in normal breast and ovarian tissue and the gene is expressed from the 
paternal allele. In 40% of breast and ovarian cancer cells; however, the paternal allele is 
also silenced by methylation, causing loss of heterozygosity (LOH) [37] [38]. It has been 
shown that re-expression of ARHI can induce apoptosis and autophagy [32] [37]. p21 is a 
cell cycle inhibitor that is usually silenced in many types of cancer cells, including 
ovarian cancers, which facilitates uncontrolled cell-cycle progression. RARβ2 is a marker 
of differentiation and is silenced by methylation, since rapid growth of tumor cells is 
antagonistic to differentiation. Theoretically, re-expression of RARβ2 can limit 
uncontrolled cell growth, the re-expression of p21 can cause cell cycle arrest, and re-
expression of ARHI may result in induction of apoptosis and autophagy. As we observed 
the re-expression of these three genes in ovarian cancer cells after HDACi treatment, we 
further investigated the effects of these inhibitors on cell cycle progression, apoptosis, 
and autophagy.  
The cell cycle profiles have revealed that HDACi in combination with calpeptin 
arrested the cell-division cycle at the S-phase in both CAOV-3 and SKOV-3 ovarian 
cancer cells, whereas calpeptin alone did not produce much inhibition (Figure 8A and B). 
Since HDACi re-expressed p21 in both CAOV-3 and SKOV-3 ovarian cancer cell lines, 
these results were expected. We are further not surprised that calpeptin was not as 
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effective in inhibiting the cell cycle progression. Inhibition of calpain is customarily 
linked to induction of apoptosis and autophagy [34].  
To measure apoptosis in the two ovarian cancer cell lines, we utilized an 
annexin/PI fluorescent apoptosis assay. The assay essentially examined the binding of 
annexin to the flipped cellular membrane during the early stage of apoptosis and made 
the membrane permeable for propidium iodide to enter the cell and bind the DNA of 
dying cells. The analysis with the assay is more precise when applied in the early phase 
of apoptosis, when most cells possess the reversed cellular membrane. In the late phase of 
apoptosis, most dying cells lose their membranes and minimum annexin binding is 
observed. Therefore, to optimize the time of initial induction of apoptosis is extremely 
important to examine a “perfect window” of cells to perform this type of assay. Figure 
5A and B indicated that HDACi and calpeptin were successful at much lower 
concentrations to inhibit the growth of CAOV-3 ovarian cancer cells as compared to 
SKOV3 ovarian cancer cells. Therefore, theoretically, we should have observed increased 
levels of apoptosis in CAOV-3 ovarian cancer cells. Induction of apoptosis however was 
more apparent in SKOV-3 ovarian cancer cells as compared to the CAOV-3 ovarian 
cancer cells (Figure 8C and D). The observed decreased amount of apoptosis is perhaps a 
reflection of the majority of cells having been already dead when the cells were harvested 
and the assay was performed. In support of this conclusion, we discovered that the 
number of live CAOV-3 ovarian cancer cells was much lower when compared to SKOV-
3 ovarian cancer cells, under the conditions of the experiment (not shown). Most of the 
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cells were smaller and rounded in shape, suggesting that they were already progressing 
through cell death.  
Autophagy is a process of degradation of cellular components through 
phagosomal and lysosomal fusion. During the formation of this phagolysosomal complex, 
cytoplasmic LC3b protein translocates to the membrane of the phagolysosome complex. 
Inhibition of calpain is known to cause autophagy [34]. In addition, the drastic change in 
morphology (Figure 5C and D) after calpain treatment (as a single agent or in 
combination) and the re-expression of ARHI (Figure 7A and B, left panel) suggested a 
possible induction of autophagy. To analyze for autophagy, we used an immuno-
fluorescent assay to detect the presence of LC3b on phagolysosomes after HDACi and 
calpeptin treatment. CAOV-3 ovarian cancer cells illustrated distinct formation of 
phagolysosomes, which contained fluorescently stained LC3b when calpeptin was used 
(Figure 8G). In SKOV-3 cancer cells, HDACi also detected LC3b on phagolysosomes, 
though in a lower amount as compared to the combination treatment. The combination of 
HDACi and calpeptin revealed the formation of phagolysosomal complexes with 
fluorescent LC3b protein in both CAOV-3 and SKOV-3 ovarian cancer cells. As 
discussed in the apoptosis assay, though we expected a larger signal of LC3b protein 
fluorescence in CAOV-3 cancer cells, the results demonstrated an apparent lower amount 
translocated, as compared to SKOV-3 cancer cells. We attribute this fact to the same 
reason that most of the CAOV-3 ovarian cancer cells were already dead and degraded 
when this assay was performed.  
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Our laboratory has previously demonstrated HDACi inhibition of DNMTI 
through the inhibition of ERK kinase in prostate cancer cells [21] [28]. In this study, we 
investigated whether HDACi and calpeptin have any effect on the ERK kinase 
phosphorylation in ovarian cancer cells (Figure 9B). HDACi SAHA inhibited ERK 
phosphorylation in both CAOV-3 and SKOV-3 ovarian cancer cells. SB and calpeptin 
alone, at the concentrations used, were not as effective. However, the combination 
treatment indicated the inhibition of ERK phosphorylation in both ovarian cancer cell 
lines. The inhibition of ERK phosphorylation suggests that in addition to the degradation 
of DNMTI to demethylate TSG for their re-expression, these drug combinations inhibit 
an imperative pro-growth signaling pathway mediated by ERK kinase.  
Interestingly, inhibition of calpain is known to negatively regulate Akt mediated 
signaling [30]. Akt is a principal kinase, anti-apoptotic in nature and often constitutively 
phosphorylated in various types of cancer cells. Inhibition of Akt phosphorylation is 
associated with induction of apoptosis and initiation of autophagy. Figure 9A illustrated 
the status of phosphorylated Akt in CAOV-3 and SKOV-3 ovarian cancer cells after 
HDACi and calpeptin treatments. The inhibition of Akt phosphorylation by calpeptin 
however, was not as prominent as hypothesized. The concentrations of calpeptin in these 
experiments were employed at 20 ug/mL. This is a sub-optimal dose for inhibition of 
calpain. The complete inhibition of calpain activity is usually achieved at 40 ug/mL. 
Though a much lower dose of calpeptin is sufficient for our combination studies, a much 
higher dose might be required in a biochemical assay to show complete inhibition of Akt 
phosphorylation. 
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In conclusion, this study has demonstrated that combination of HDACi and 
calpeptin is effective against the growth of ovarian cancer cells, though the inhibitory 
concentrations vary for CAOV-3 and SKOV-3 ovarian cancer cell lines. The apparent 
reduction of viable cells was a result of cell cycle arrest, induction of apoptosis and 
autophagy. We observed the re-expression of three epigenetically silenced TSG: ARHI, 
p21, and RARβ2 designating their roles in the above processes. In addition to regulating 
methylation process, the inhibition of ERK and Akt kinases presumably played a role in 
growth inhibition and induction of apoptosis and autophagy. Regulation of epigenetic 
silencing of TSG by ERK and Akt is a current focus of our laboratory, however it is 
beyond the scope of this thesis proposal. These findings provide an understanding of how 
these inhibitors are involved in upregulating different pathways, which block cancer cell 
growth and induce apoptosis and autophagy. Our results suggest that the combination of 
epigenetic drugs with other cytotoxic agents can generate improved therapies and 
treatment for ovarian cancer. 
 
 
 
 
 
 
 
 
 
 33 
REFERENCES 
 
1. U.S. Cancer Statistics Working Group. (2015). United States Cancer Statistics: 1999–2012 
Incidence and Mortality Web-based Report. Department of Health and Human Services, 
Centers for Disease Control and Prevention, and National Cancer Institute. 
2. Zweemer, R. P., Verheijen, R. H., Menko, F. H., Gille, J. J., van Diest, P. J., Coebergh, J. 
W., … Kenemans, P. (1999). Differences between hereditary and sporadic ovarian cancer. 
European Journal of Obstetrics, Gynecology, and Reproductive Biology, 82(2), 151–153. 
3. Mataga, M. A., Rosenthal, S., Heerboth, S., Devalapalli, A., Kokolus, S., Evans, L. R., … 
Sarkar, S. (2012). Anti-breast Cancer Effects of Histone Deacetylase Inhibitors and 
Calpain Inhibitor. Anticancer Research, 32(7), 2523–2529. 
4. Sarkar, S., Horn, G., Moulton, K., Oza, A., Byler, S., Kokolus, S., & Longacre, M. (2013). 
Cancer Development, Progression, and Therapy: An Epigenetic Overview. International 
Journal of Molecular Sciences, 14(10), 21087–21113. http://doi.org/10.3390/ijms1410210 
5. Rhoda, K., Choonara, Y. E., Kumar, P., Bijukumar, D., Toit, L. C. du, & Pillay, V. (2015). 
Potential nanotechnologies and molecular targets in the quest for efficient chemotherapy in 
ovarian cancer. Expert Opinion on Drug Delivery, 12(4), 613–634. 
http://doi.org/10.1517/17425247.2015.970162 
6. Tomasina, J., Lheureux, S., Gauduchon, P., Rault, S., & Malzert-Fréon, A. (2013). 
Nanocarriers for the targeted treatment of ovarian cancers. Biomaterials, 34(4), 1073–1101. 
http://doi.org/10.1016/j.biomaterials.2012.10.055 
 34 
7. Davis, A., Tinker, A. V., & Friedlander, M. (2014). “Platinum resistant” ovarian cancer: 
What is it, who to treat and how to measure benefit? Gynecologic Oncology, 133(3), 624–
631. http://doi.org/10.1016/j.ygyno.2014.02.038 
8. Bhoola, S., & Hoskins, W. J. (2006). Diagnosis and Management of Epithelial Ovarian 
Cancer: Obstetrics & Gynecology, 107(6), 1399–1410. 
http://doi.org/10.1097/01.AOG.0000220516.34053.48 
9. Feil, R., & Fraga, M. F. (2012). Epigenetics and the environment: emerging patterns and 
implications. Nature Reviews Genetics, 13(2), 97–109. http://doi.org/10.1038/nrg3142 
10. Housman, G., Byler, S., Heerboth, S., Lapinska, K., Longacre, M., Snyder, N., & Sarkar, S. 
(2014). Drug resistance in cancer: an overview. Cancers, 6(3), 1769–1792. 
http://doi.org/10.3390/cancers6031769 
11. Heerboth, S., Housman, G., Leary, M., Longacre, M., Byler, S., Lapinska, K., … Sarkar, S. 
(2015). EMT and tumor metastasis. Clinical and Translational Medicine, 4, 6. 
http://doi.org/10.1186/s40169-015-0048-3 
12. Sharma, S., Kelly, T. K., & Jones, P. A. (2010). Epigenetics in cancer. Carcinogenesis, 
31(1), 27–36. http://doi.org/10.1093/carcin/bgp220 
13. Bannister, A. J., & Kouzarides, T. (2011). Regulation of chromatin by histone 
modifications. Cell Research, 21(3), 381–395. http://doi.org/10.1038/cr.2011.22 
14. Füllgrabe, J., Kavanagh, E., & Joseph, B. (2011). Histone onco-modifications. Oncogene, 
30(31), 3391–3403. http://doi.org/10.1038/onc.2011.121 
 35 
15. Khan, O., & La Thangue, N. B. (2012). HDAC inhibitors in cancer biology: emerging 
mechanisms and clinical applications. Immunology and Cell Biology, 90(1), 85–94. 
http://doi.org/10.1038/icb.2011.100 
16. Zhang, C., Richon, V., Ni, X., Talpur, R., & Duvic, M. (2005). Selective Induction of 
Apoptosis by Histone Deacetylase Inhibitor SAHA in Cutaneous T-Cell Lymphoma Cells: 
Relevance to Mechanism of Therapeutic Action. Journal of Investigative Dermatology, 
125(5), 1045–1052. http://doi.org/10.1111/j.0022-202X.2005.23925.x 
17. Miller, C. P., Singh, M. M., Rivera-Del Valle, N., Manton, C. A., & Chandra, J. (2011). 
Therapeutic Strategies to Enhance the Anticancer Efficacy of Histone Deacetylase 
Inhibitors. Journal of Biomedicine and Biotechnology, 2011. 
http://doi.org/10.1155/2011/514261 
18. Byler, S., Goldgar, S., Heerboth, S., Leary, M., Housman, G., Moulton, K., & Sarkar, S. 
(2014). Genetic and epigenetic aspects of breast cancer progression and therapy. 
Anticancer Research, 34(3), 1071–1077. 
19. Robertson, K. D., Keyomarsi, K., Gonzales, F. A., Velicescu, M., & Jones, P. A. (2000). 
Differential mRNA expression of the human DNA methyltransferases (DNMTs) 1, 3a and 
3b during the G(0)/G(1) to S phase transition in normal and tumor cells. Nucleic Acids 
Research, 28(10), 2108–2113. 
20. Jones, P. A., & Laird, P. W. (1999). Cancer-epigenetics comes of age. Nature Genetics, 
21(2), 163–167. http://doi.org/10.1038/5947 
 36 
21. Sarkar, S., Goldgar, S., Byler, S., Rosenthal, S., & Heerboth, S. (2013). Demethylation and 
re-expression of epigenetically silenced tumor suppressor genes: sensitization of cancer 
cells by combination therapy. Epigenomics, 5(1), 87–94. http://doi.org/10.2217/epi.12.68 
22. Dong, L. M., Potter, J. D., White, E., Ulrich, C. M., Cardon, L. R., & Peters, U. (2008). 
Genetic Susceptibility to Cancer: the Role of Polymorphisms in Candidate Genes. JAMA  : 
The Journal of the American Medical Association, 299(20), 2423–2436. 
http://doi.org/10.1001/jama.299.20.2423 
23. Fraga, M. F., Ballestar, E., Paz, M. F., Ropero, S., Setien, F., Ballestar, M. L., … Esteller, 
M. (2005). Epigenetic differences arise during the lifetime of monozygotic twins. 
Proceedings of the National Academy of Sciences of the United States of America, 102(30), 
10604–10609. http://doi.org/10.1073/pnas.0500398102 
24. Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. Cell, 
144(5), 646–674. http://doi.org/10.1016/j.cell.2011.02.013 
25. Vinogradov, S., & Wei, X. (2012). Cancer stem cells and drug resistance: the potential of 
nanomedicine. Nanomedicine (London, England), 7(4), 597–615. 
http://doi.org/10.2217/nnm.12.22 
26. Cacan, E., Ali, M. W., Boyd, N. H., Hooks, S. B., & Greer, S. F. (2014). Inhibition of 
HDAC1 and DNMT1 modulate RGS10 expression and decrease ovarian cancer 
chemoresistance. PloS One, 9(1), e87455. http://doi.org/10.1371/journal.pone.0087455 
27. Sarkar, S., Abujamra, A. L., Loew, J. E., Forman, L. W., Perrine, S. P., & Faller, D. V. 
(2011). Histone deacetylase inhibitors reverse CpG methylation by regulating DNMT1 
through ERK signaling. Anticancer Research, 31(9), 2723–2732. 
 37 
28. Sarkar, S., & Faller, D. V. (2011). T-oligos inhibit growth and induce apoptosis in human 
ovarian cancer cells. Oligonucleotides, 21(1), 47–53. http://doi.org/10.1089/oli.2010.0259 
29. Lu, Z., Yang, H., Sutton, M. N., Yang, M., Clarke, C. H., Liao, W. S.-L., & Bast, R. C. 
(2014). ARHI (DIRAS3) induces autophagy in ovarian cancer cells by downregulating the 
epidermal growth factor receptor, inhibiting PI3K and Ras/MAP signaling and activating 
the FOXo3a-mediated induction of Rab7. Cell Death and Differentiation, 21(8), 1275–
1289. http://doi.org/10.1038/cdd.2014.48 
30. Ho, W., Pikor, L., Gao, Y., Elliott, B. E., & Greer, P. A. (2012). Calpain 2 Regulates Akt-
FoxO-p27Kip1 Protein Signaling Pathway in Mammary Carcinoma. The Journal of 
Biological Chemistry, 287(19), 15458–15465. http://doi.org/10.1074/jbc.M112.349308 
31. Frew, A. J., Lindemann, R. K., Martin, B. P., Clarke, C. J. P., Sharkey, J., Anthony, D. A., 
… Johnstone, R. W. (2008). Combination therapy of established cancer using a histone 
deacetylase inhibitor and a TRAIL receptor agonist. Proceedings of the National Academy 
of Sciences, 105(32), 11317–11322. http://doi.org/10.1073/pnas.0801868105 
32. Fujii, S., Luo, R. Z., Yuan, J., Kadota, M., Oshimura, M., Dent, S. R., … Yu, Y. (2003). 
Reactivation of the silenced and imprinted alleles of ARHI is associated with increased 
histone H3 acetylation and decreased histone H3 lysine 9 methylation. Human Molecular 
Genetics, 12(15), 1791–1800. 
33. Sarkar, S., & Faller, D. V. (2013). Telomere-Homologous G-Rich Oligonucleotides 
Sensitize Human Ovarian Cancer Cells to TRAIL-Induced Growth Inhibition and 
Apoptosis. Nucleic Acid Therapeutics, 23(3), 167–174. 
http://doi.org/10.1089/nat.2012.0401 
 38 
34. Storr, S. J., Carragher, N. O., Frame, M. C., Parr, T., & Martin, S. G. (2011). The calpain 
system and cancer. Nature Reviews Cancer, 11(5), 364–374. 
http://doi.org/10.1038/nrc3050 
35. Sarkar, S. (2013). Methods for Identifying Compounds Treatment of Thrombotic 
Condition. Patent Number: US 8,586,292B2 
36. Flaumenhaft, R. (2006). Formation and fate of platelet microparticles. Blood Cells, 
Molecules, and Diseases, 36(2), 182–187. http://doi.org/10.1016/j.bcmd.2005.12.019 
37.  Bast, R. C., Hennessy, B., & Mills, G. B. (2009). The biology of ovarian cancer: new 
opportunities for translation. Nature Reviews. Cancer, 9(6), 415. 
http://doi.org/10.1038/nrc2644 
38. Yu, Y., Fujii, S., Yuan, J., Luo, R. Z., Wang, L., Bao, J., … Bast, R. C. (2003). Epigenetic 
regulation of ARHI in breast and ovarian cancer cells. Annals of the New York Academy of 
Sciences, 983, 268–277. 
 
 
 
 
 
 
 
 
 39 
CURRICULUM VITAE 
 40 
 41 
